Spleen tyrosine kinase inhibitors - Pipeline Insight, 2025

This “Spleen tyrosine kinase inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Spleen tyrosine kinase inhibitors Understanding

Spleen tyrosine kinase inhibitors: Overview

Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk inhibitors are a new group of small molecule inhibitors targeting BCR-mediated signaling pathways.

Syk was recognized as a critical element in the BCR signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk along with other BCR signaling molecules, Bruton tyrosine kinase (BTK), PI3K delta (PI3Kδ), and tumor necrosis factor (TNF) superfamily receptors was also found to be involved in signal transduction independent from the BCR. Syk is expressed primarily in hematopoietic cells like B-cells, monocytes, macrophages, mast cells, and neutrophils. Syk was recognized to be a potential target for the treatment of various hematologic cancers, autoimmune disorders, and other inflammatory states.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Spleen tyrosine kinase inhibitors R&D. The therapies under development are focused on novel approaches for Spleen tyrosine kinase inhibitors.

Spleen tyrosine kinase inhibitors Emerging Drugs Chapters

This segment of the Spleen tyrosine kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spleen tyrosine kinase inhibitors Emerging Drugs

Fostamatinib: Rigel Pharmaceuticals

Fostamatinib is a selective, oral spleen tyrosine kinase (SYK) inhibitor being evaluated for Autoimmune haemolytic anaemia, COVID-19 which is currently in Phase III stage of development and is being developed by Rigel Pharmaceuticals.

• Entospletinib: Kronos Bio

Entospletinib (ENTO), is a selective inhibitor targeting SYK, a critical node in a dysregulated TRN within AML defined by persistent high expression of the transcription factors HOXA9 and MEIS1 (HOX/MEIS). It is currently in Phase II stage of development for the treatment of Acute myeloid leukaemia and is being developed by Kronos Bio.

Spleen tyrosine kinase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Spleen tyrosine kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Spleen tyrosine kinase inhibitors

There are approx. 10+ key companies which are developing the Spleen tyrosine kinase inhibitors. The companies which have their Spleen tyrosine kinase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Rigel Pharmaceuticals.

Phases

The report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Spleen tyrosine kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spleen tyrosine kinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Spleen tyrosine kinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen tyrosine kinase inhibitors drugs.

Spleen tyrosine kinase inhibitors Report Insights

• Spleen tyrosine kinase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spleen tyrosine kinase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Spleen tyrosine kinase inhibitors drugs?
• How many Spleen tyrosine kinase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Spleen tyrosine kinase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spleen tyrosine kinase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spleen tyrosine kinase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Dermavant Sciences
• Rigel Pharmaceuticals
• Kronos Bio
• Hutchison MediPharma
• Hanmi Pharmaceutical
• Genosco
• Asana BioSciences

Key Products

• Cerdulatinib
• Fostamatinib
• Entospletinib
• Lanraplenib
• HMPL-523
• HM43239
• SKI O 703
• ASN002

This product will be delivered within 2 business days.